SLNO Soleno Therapeutics
- 41.8250
- -1.0450-2.44%
Soleno Therapeutics News
Soleno Therapeutics | 8-K: Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Soleno Therapeutics | 10-Q: Quarterly report
Soleno Therapeutics | 8-K: Current report
Soleno Therapeutics | 424B5: Prospectus
Soleno Therapeutics | 424B5: Prospectus
Soleno Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Vivo Opportunity Fund Holdings, L.P.(22.5%),Vivo Opportunity, LLC(22.5%)
Soleno Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Vivo Opportunity, LLC
Soleno Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Manning Meredith
Soleno Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Huang Michael F.
Soleno Therapeutics | 8-K: Current report
Soleno Therapeutics | ARS: Annual Report to Security Holders
Soleno Therapeutics | DEF 14A: Definitive information statements
Soleno Therapeutics | 8-K: Current report
Soleno Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Yen Kristen
Soleno Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Mackaness James H
Soleno Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hirano Patricia C
Soleno Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Anish Bhatnagar
Soleno Therapeutics | 10-K: Annual report
Soleno Therapeutics | 8-K: Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Soleno Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Commodore Capital LP(2.3%),Commodore Capital Master LP(2.3%)
Analysis
Price Target
No Data
